| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electron Spin Resonance Spectroscopy | 88 | 2024 | 317 | 17.530 |
Why?
|
| Oxygen | 44 | 2024 | 743 | 10.790 |
Why?
|
| Molecular Imaging | 12 | 2024 | 65 | 4.400 |
Why?
|
| Fibrosarcoma | 14 | 2020 | 85 | 3.750 |
Why?
|
| Image Processing, Computer-Assisted | 24 | 2024 | 1242 | 3.740 |
Why?
|
| Oximetry | 13 | 2020 | 82 | 3.580 |
Why?
|
| Algorithms | 20 | 2024 | 1877 | 3.080 |
Why?
|
| Imaging, Three-Dimensional | 15 | 2024 | 598 | 3.050 |
Why?
|
| Phantoms, Imaging | 22 | 2024 | 448 | 2.650 |
Why?
|
| Diagnostic Imaging | 12 | 2021 | 479 | 2.100 |
Why?
|
| Neoplasms, Experimental | 10 | 2016 | 269 | 1.980 |
Why?
|
| Spin Labels | 24 | 2023 | 106 | 1.890 |
Why?
|
| Hypoxia | 10 | 2022 | 653 | 1.710 |
Why?
|
| Tumor Hypoxia | 6 | 2022 | 31 | 1.710 |
Why?
|
| Mice, Inbred C3H | 20 | 2017 | 371 | 1.590 |
Why?
|
| Neoplasms | 17 | 2024 | 3041 | 1.550 |
Why?
|
| Electrons | 3 | 2017 | 50 | 1.310 |
Why?
|
| Radiotherapy, Image-Guided | 3 | 2018 | 58 | 1.270 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2020 | 176 | 1.260 |
Why?
|
| Animals | 63 | 2024 | 27371 | 1.220 |
Why?
|
| Oxidation-Reduction | 7 | 2023 | 388 | 1.200 |
Why?
|
| Mice | 40 | 2022 | 11761 | 1.190 |
Why?
|
| Magnetic Resonance Imaging | 18 | 2021 | 3448 | 1.150 |
Why?
|
| Signal Processing, Computer-Assisted | 5 | 2014 | 202 | 1.030 |
Why?
|
| Cell Hypoxia | 8 | 2022 | 170 | 0.920 |
Why?
|
| Trityl Compounds | 5 | 2017 | 6 | 0.920 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2014 | 125 | 0.820 |
Why?
|
| Sulfhydryl Compounds | 3 | 2023 | 71 | 0.770 |
Why?
|
| Reproducibility of Results | 12 | 2018 | 2758 | 0.750 |
Why?
|
| Image Enhancement | 5 | 2017 | 567 | 0.710 |
Why?
|
| Radiation Tolerance | 2 | 2013 | 173 | 0.710 |
Why?
|
| Tissue Engineering | 2 | 2017 | 185 | 0.630 |
Why?
|
| Free Radicals | 8 | 2019 | 71 | 0.610 |
Why?
|
| Cyclic N-Oxides | 8 | 2013 | 33 | 0.610 |
Why?
|
| Transplants | 1 | 2017 | 41 | 0.580 |
Why?
|
| Muscle Neoplasms | 1 | 2017 | 18 | 0.560 |
Why?
|
| Magnetic Fields | 1 | 2016 | 11 | 0.560 |
Why?
|
| Signal-To-Noise Ratio | 5 | 2018 | 103 | 0.550 |
Why?
|
| Sensitivity and Specificity | 9 | 2015 | 2015 | 0.550 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2017 | 312 | 0.540 |
Why?
|
| Oxidative Stress | 3 | 2023 | 458 | 0.540 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2022 | 2661 | 0.530 |
Why?
|
| Bone Marrow | 1 | 2017 | 445 | 0.520 |
Why?
|
| Osteogenesis | 1 | 2017 | 255 | 0.520 |
Why?
|
| Antigens, Neoplasm | 2 | 2017 | 332 | 0.510 |
Why?
|
| Computer Graphics | 2 | 2015 | 100 | 0.510 |
Why?
|
| Nitrogen Oxides | 8 | 2016 | 15 | 0.500 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2013 | 688 | 0.480 |
Why?
|
| Partial Pressure | 5 | 2017 | 50 | 0.470 |
Why?
|
| Radiotherapy Dosage | 7 | 2017 | 470 | 0.460 |
Why?
|
| Artifacts | 3 | 2018 | 247 | 0.460 |
Why?
|
| Cell Line, Tumor | 9 | 2019 | 2558 | 0.440 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2014 | 71 | 0.440 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2013 | 424 | 0.430 |
Why?
|
| Computer Simulation | 5 | 2018 | 1097 | 0.430 |
Why?
|
| Oxygen Consumption | 4 | 2020 | 244 | 0.420 |
Why?
|
| Hindlimb | 4 | 2014 | 95 | 0.400 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 782 | 0.370 |
Why?
|
| Hydroxyl Radical | 4 | 2000 | 35 | 0.370 |
Why?
|
| Glutathione | 2 | 2023 | 108 | 0.350 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 7 | 2020 | 179 | 0.340 |
Why?
|
| Humans | 49 | 2024 | 89357 | 0.340 |
Why?
|
| Printing, Three-Dimensional | 2 | 2020 | 40 | 0.320 |
Why?
|
| Adenocarcinoma | 5 | 2013 | 1194 | 0.310 |
Why?
|
| Radiation-Protective Agents | 2 | 2012 | 98 | 0.310 |
Why?
|
| Carcinoma | 2 | 2010 | 443 | 0.290 |
Why?
|
| Electromagnetic Fields | 4 | 2014 | 26 | 0.280 |
Why?
|
| X-Ray Microtomography | 2 | 2017 | 90 | 0.280 |
Why?
|
| Urinary Catheterization | 1 | 2006 | 36 | 0.270 |
Why?
|
| Superoxides | 5 | 2004 | 74 | 0.250 |
Why?
|
| Radiotherapy, Conformal | 3 | 2015 | 84 | 0.250 |
Why?
|
| Misonidazole | 2 | 2022 | 17 | 0.240 |
Why?
|
| Half-Life | 6 | 2017 | 97 | 0.240 |
Why?
|
| Urinary Bladder | 1 | 2006 | 246 | 0.230 |
Why?
|
| Data Interpretation, Statistical | 3 | 2013 | 299 | 0.220 |
Why?
|
| Amifostine | 1 | 2003 | 51 | 0.210 |
Why?
|
| Principal Component Analysis | 2 | 2014 | 160 | 0.210 |
Why?
|
| Pyridines | 3 | 2000 | 315 | 0.210 |
Why?
|
| Mice, Nude | 4 | 2019 | 815 | 0.210 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2022 | 1096 | 0.210 |
Why?
|
| Mammals | 1 | 2024 | 235 | 0.200 |
Why?
|
| Calibration | 2 | 2017 | 104 | 0.190 |
Why?
|
| Female | 21 | 2020 | 46202 | 0.190 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2020 | 296 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 3 | 2013 | 1057 | 0.190 |
Why?
|
| High-Intensity Focused Ultrasound Ablation | 1 | 2021 | 43 | 0.180 |
Why?
|
| Kinetics | 6 | 2016 | 1528 | 0.180 |
Why?
|
| Rabbits | 2 | 2013 | 639 | 0.180 |
Why?
|
| Models, Biological | 2 | 2017 | 1765 | 0.180 |
Why?
|
| Body Water | 1 | 1999 | 35 | 0.170 |
Why?
|
| Nitric Oxide | 4 | 2009 | 279 | 0.170 |
Why?
|
| Rats | 7 | 2013 | 4041 | 0.170 |
Why?
|
| Tritium | 2 | 2016 | 133 | 0.170 |
Why?
|
| X-Rays | 2 | 2006 | 135 | 0.160 |
Why?
|
| Contrast Media | 3 | 2020 | 1091 | 0.160 |
Why?
|
| Homologous Recombination | 1 | 2019 | 52 | 0.160 |
Why?
|
| Prostatic Neoplasms | 7 | 2009 | 1769 | 0.160 |
Why?
|
| Indoles | 1 | 2000 | 314 | 0.160 |
Why?
|
| Radio Waves | 2 | 2017 | 15 | 0.150 |
Why?
|
| Molecular Structure | 5 | 2005 | 290 | 0.150 |
Why?
|
| Carbon Dioxide | 2 | 1996 | 202 | 0.150 |
Why?
|
| Chitosan | 1 | 2017 | 18 | 0.150 |
Why?
|
| Gamma Rays | 1 | 2017 | 73 | 0.150 |
Why?
|
| Nanoparticles | 1 | 2019 | 164 | 0.150 |
Why?
|
| Reperfusion Injury | 1 | 2019 | 141 | 0.150 |
Why?
|
| Free Radical Scavengers | 2 | 2012 | 59 | 0.150 |
Why?
|
| Buthionine Sulfoximine | 1 | 2016 | 7 | 0.140 |
Why?
|
| Indenes | 1 | 2017 | 10 | 0.140 |
Why?
|
| Indolequinones | 1 | 2016 | 1 | 0.140 |
Why?
|
| Deuterium | 1 | 2017 | 33 | 0.140 |
Why?
|
| Quantum Theory | 1 | 2017 | 32 | 0.140 |
Why?
|
| Tissue Distribution | 2 | 2013 | 293 | 0.140 |
Why?
|
| Disulfides | 1 | 2016 | 64 | 0.140 |
Why?
|
| Fourier Analysis | 2 | 2007 | 126 | 0.140 |
Why?
|
| Image-Guided Biopsy | 1 | 2017 | 68 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 860 | 0.130 |
Why?
|
| Gonadotropins, Pituitary | 1 | 1995 | 11 | 0.130 |
Why?
|
| Fluorocarbons | 1 | 1996 | 72 | 0.130 |
Why?
|
| Collagen | 1 | 2017 | 293 | 0.130 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1996 | 97 | 0.130 |
Why?
|
| Absorption, Radiation | 1 | 2015 | 4 | 0.130 |
Why?
|
| Radiotherapy, Computer-Assisted | 1 | 2015 | 25 | 0.130 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 63 | 0.130 |
Why?
|
| Skin Physiological Phenomena | 1 | 2015 | 27 | 0.130 |
Why?
|
| Genetic Therapy | 2 | 2009 | 370 | 0.130 |
Why?
|
| Sarcoma, Experimental | 1 | 1994 | 53 | 0.120 |
Why?
|
| Biophysical Phenomena | 2 | 2010 | 124 | 0.120 |
Why?
|
| Solutions | 3 | 2005 | 86 | 0.120 |
Why?
|
| Positron-Emission Tomography | 3 | 2022 | 337 | 0.120 |
Why?
|
| Androgens | 1 | 1995 | 176 | 0.120 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 329 | 0.120 |
Why?
|
| Halothane | 1 | 1994 | 12 | 0.120 |
Why?
|
| Radiotherapy | 4 | 2013 | 333 | 0.120 |
Why?
|
| Electronics | 1 | 2014 | 17 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 2 | 1995 | 360 | 0.110 |
Why?
|
| Anesthesia, Inhalation | 1 | 1994 | 36 | 0.110 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2014 | 47 | 0.110 |
Why?
|
| Anisotropy | 1 | 2014 | 63 | 0.110 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2014 | 64 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 120 | 0.110 |
Why?
|
| Myasthenia Gravis | 1 | 1994 | 83 | 0.110 |
Why?
|
| Nitrous Oxide | 1 | 1994 | 107 | 0.110 |
Why?
|
| ROC Curve | 1 | 2016 | 781 | 0.110 |
Why?
|
| Radiobiology | 1 | 2013 | 13 | 0.110 |
Why?
|
| Mitochondrial Proteins | 1 | 2014 | 127 | 0.110 |
Why?
|
| Liposomes | 2 | 2010 | 93 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 308 | 0.100 |
Why?
|
| Reactive Oxygen Species | 3 | 2012 | 490 | 0.100 |
Why?
|
| Hydroxylamine | 1 | 2012 | 5 | 0.100 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2012 | 61 | 0.100 |
Why?
|
| Myocardium | 4 | 2002 | 571 | 0.100 |
Why?
|
| Brain Chemistry | 1 | 2012 | 122 | 0.100 |
Why?
|
| Endocytosis | 2 | 2010 | 180 | 0.100 |
Why?
|
| Pyrrolidines | 3 | 2004 | 59 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1525 | 0.090 |
Why?
|
| Proteins | 1 | 2016 | 787 | 0.090 |
Why?
|
| Survival Rate | 3 | 2013 | 1901 | 0.090 |
Why?
|
| Hydroxides | 1 | 1990 | 9 | 0.090 |
Why?
|
| Cisplatin | 2 | 1994 | 618 | 0.090 |
Why?
|
| Breast Neoplasms | 7 | 2010 | 3011 | 0.090 |
Why?
|
| Molecular Probes | 1 | 2010 | 35 | 0.090 |
Why?
|
| Cell Physiological Phenomena | 1 | 1990 | 24 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 1995 | 1549 | 0.090 |
Why?
|
| Prognosis | 4 | 2013 | 3783 | 0.090 |
Why?
|
| Temperature | 3 | 2016 | 404 | 0.090 |
Why?
|
| DNA Damage | 1 | 1991 | 371 | 0.080 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2010 | 83 | 0.080 |
Why?
|
| Perfusion Imaging | 1 | 2009 | 50 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2014 | 2001 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 1597 | 0.080 |
Why?
|
| Subtraction Technique | 1 | 2009 | 132 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 179 | 0.080 |
Why?
|
| Equipment Design | 3 | 2015 | 417 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 246 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2019 | 3385 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 2 | 2013 | 1063 | 0.070 |
Why?
|
| Statistical Distributions | 1 | 2006 | 9 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1224 | 0.070 |
Why?
|
| Software | 2 | 2011 | 665 | 0.070 |
Why?
|
| Administration, Intravesical | 1 | 2006 | 34 | 0.070 |
Why?
|
| Spectrophotometry | 1 | 2006 | 108 | 0.070 |
Why?
|
| Molecular Conformation | 2 | 2005 | 96 | 0.070 |
Why?
|
| Sample Size | 1 | 2006 | 128 | 0.070 |
Why?
|
| Remission Induction | 1 | 2008 | 740 | 0.070 |
Why?
|
| Models, Chemical | 1 | 2007 | 179 | 0.070 |
Why?
|
| Xanthine | 3 | 2003 | 6 | 0.070 |
Why?
|
| Radionuclide Imaging | 1 | 2006 | 221 | 0.070 |
Why?
|
| Xanthine Oxidase | 3 | 2003 | 25 | 0.060 |
Why?
|
| Radon | 1 | 2005 | 4 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2007 | 471 | 0.060 |
Why?
|
| Elastin | 1 | 2004 | 8 | 0.060 |
Why?
|
| Thermometers | 1 | 2004 | 6 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2006 | 470 | 0.060 |
Why?
|
| Thermography | 1 | 2004 | 14 | 0.060 |
Why?
|
| Microwaves | 2 | 2017 | 36 | 0.060 |
Why?
|
| Indicators and Reagents | 2 | 2002 | 72 | 0.060 |
Why?
|
| Esters | 1 | 2003 | 30 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 1412 | 0.050 |
Why?
|
| Injections, Intraperitoneal | 1 | 2003 | 101 | 0.050 |
Why?
|
| Biological Availability | 1 | 2003 | 92 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2003 | 42 | 0.050 |
Why?
|
| Nitric Oxide Donors | 1 | 2002 | 12 | 0.050 |
Why?
|
| Nitroprusside | 1 | 2002 | 32 | 0.050 |
Why?
|
| Chemistry, Organic | 1 | 2002 | 2 | 0.050 |
Why?
|
| Dioxoles | 1 | 2002 | 7 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2006 | 576 | 0.050 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2002 | 31 | 0.050 |
Why?
|
| Vasospasm, Intracranial | 1 | 2002 | 35 | 0.050 |
Why?
|
| Pyrroles | 1 | 2003 | 187 | 0.050 |
Why?
|
| Biomedical Research | 2 | 2003 | 398 | 0.050 |
Why?
|
| Flavanones | 1 | 2002 | 35 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 277 | 0.050 |
Why?
|
| Flavonoids | 1 | 2002 | 87 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 682 | 0.050 |
Why?
|
| Acoustics | 1 | 2021 | 51 | 0.050 |
Why?
|
| Microbubbles | 1 | 2021 | 36 | 0.050 |
Why?
|
| Mesencephalon | 1 | 2001 | 64 | 0.050 |
Why?
|
| X-Ray Film | 1 | 2020 | 36 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 193 | 0.050 |
Why?
|
| Peptides | 1 | 2004 | 648 | 0.050 |
Why?
|
| Polyesters | 1 | 2020 | 41 | 0.050 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 48 | 0.050 |
Why?
|
| Organ Sparing Treatments | 1 | 2020 | 46 | 0.050 |
Why?
|
| Equipment Failure Analysis | 2 | 2015 | 89 | 0.050 |
Why?
|
| Antioxidants | 1 | 2002 | 226 | 0.050 |
Why?
|
| Copper | 1 | 2020 | 78 | 0.040 |
Why?
|
| Lung Neoplasms | 5 | 1995 | 2362 | 0.040 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2021 | 93 | 0.040 |
Why?
|
| Optical Imaging | 1 | 2020 | 50 | 0.040 |
Why?
|
| Viscosity | 1 | 1999 | 46 | 0.040 |
Why?
|
| Phenotype | 1 | 2006 | 2440 | 0.040 |
Why?
|
| Dopamine | 1 | 2001 | 276 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2001 | 146 | 0.040 |
Why?
|
| Iron Chelating Agents | 1 | 1999 | 4 | 0.040 |
Why?
|
| Radiation Injuries | 3 | 1997 | 162 | 0.040 |
Why?
|
| Neoplasm Transplantation | 2 | 2003 | 397 | 0.040 |
Why?
|
| Multimodal Imaging | 1 | 2020 | 111 | 0.040 |
Why?
|
| Cell Line | 2 | 1996 | 2496 | 0.040 |
Why?
|
| Porosity | 1 | 2019 | 60 | 0.040 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2019 | 12 | 0.040 |
Why?
|
| Fluorescence | 1 | 2019 | 103 | 0.040 |
Why?
|
| Silicon Dioxide | 1 | 2019 | 40 | 0.040 |
Why?
|
| Ubiquitins | 1 | 2019 | 38 | 0.040 |
Why?
|
| Heart | 1 | 2002 | 574 | 0.040 |
Why?
|
| Combined Modality Therapy | 6 | 2009 | 1719 | 0.040 |
Why?
|
| Knee Joint | 1 | 2019 | 165 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2001 | 899 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2020 | 302 | 0.040 |
Why?
|
| Aged, 80 and over | 8 | 1997 | 6811 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2013 | 988 | 0.040 |
Why?
|
| Rectal Diseases | 1 | 1997 | 24 | 0.040 |
Why?
|
| Hydrocarbons, Brominated | 1 | 1996 | 4 | 0.030 |
Why?
|
| Male | 10 | 2019 | 42411 | 0.030 |
Why?
|
| Biophysics | 1 | 1996 | 153 | 0.030 |
Why?
|
| Hemibody Irradiation | 1 | 1995 | 1 | 0.030 |
Why?
|
| Middle Aged | 12 | 2013 | 25974 | 0.030 |
Why?
|
| Binding Sites | 2 | 2016 | 1117 | 0.030 |
Why?
|
| Hemoglobin A | 1 | 1995 | 8 | 0.030 |
Why?
|
| Rectum | 1 | 1997 | 148 | 0.030 |
Why?
|
| Chromatin | 1 | 2019 | 397 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 1214 | 0.030 |
Why?
|
| Platelet Count | 1 | 1995 | 93 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1995 | 223 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 540 | 0.030 |
Why?
|
| Transducers | 1 | 2015 | 42 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 1995 | 121 | 0.030 |
Why?
|
| Cell Division | 1 | 1996 | 696 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 226 | 0.030 |
Why?
|
| Vital Capacity | 1 | 1994 | 68 | 0.030 |
Why?
|
| Aged | 10 | 2001 | 19165 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 283 | 0.030 |
Why?
|
| Quality Control | 1 | 2013 | 117 | 0.030 |
Why?
|
| Dermatitis | 1 | 2013 | 34 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1993 | 49 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 1993 | 15 | 0.030 |
Why?
|
| Symporters | 1 | 2013 | 108 | 0.030 |
Why?
|
| Erythropoietin | 1 | 1993 | 90 | 0.030 |
Why?
|
| Alcohol Dehydrogenase | 1 | 1993 | 42 | 0.030 |
Why?
|
| Neoplasm Staging | 3 | 1997 | 2018 | 0.030 |
Why?
|
| Time Factors | 4 | 1995 | 5338 | 0.030 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 1991 | 1120 | 0.030 |
Why?
|
| Anemia | 1 | 1993 | 130 | 0.030 |
Why?
|
| Respiration | 1 | 1994 | 267 | 0.030 |
Why?
|
| Incidence | 2 | 1994 | 1595 | 0.020 |
Why?
|
| Spin Trapping | 2 | 2003 | 4 | 0.020 |
Why?
|
| Logistic Models | 1 | 1995 | 1213 | 0.020 |
Why?
|
| Memory | 1 | 1994 | 220 | 0.020 |
Why?
|
| Triacetoneamine-N-Oxyl | 1 | 1991 | 3 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 495 | 0.020 |
Why?
|
| Technology, Radiologic | 1 | 1992 | 104 | 0.020 |
Why?
|
| Movement | 1 | 2013 | 309 | 0.020 |
Why?
|
| Background Radiation | 1 | 2011 | 1 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1991 | 157 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2009 | 2884 | 0.020 |
Why?
|
| Supratentorial Neoplasms | 1 | 1990 | 10 | 0.020 |
Why?
|
| Drug Resistance | 1 | 1991 | 232 | 0.020 |
Why?
|
| Cricetinae | 1 | 1991 | 558 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 1994 | 461 | 0.020 |
Why?
|
| Vulva | 1 | 1990 | 23 | 0.020 |
Why?
|
| Astrocytoma | 1 | 1990 | 82 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 1995 | 1714 | 0.020 |
Why?
|
| Peroxidases | 1 | 1990 | 34 | 0.020 |
Why?
|
| Vulvar Neoplasms | 1 | 1990 | 20 | 0.020 |
Why?
|
| Vitamin K | 1 | 1990 | 25 | 0.020 |
Why?
|
| Cells | 1 | 1990 | 32 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1994 | 900 | 0.020 |
Why?
|
| Trastuzumab | 1 | 2010 | 74 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2013 | 8241 | 0.020 |
Why?
|
| Prostate | 1 | 1992 | 393 | 0.020 |
Why?
|
| Treatment Failure | 2 | 2002 | 287 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 428 | 0.020 |
Why?
|
| Adult | 8 | 1997 | 26607 | 0.020 |
Why?
|
| Transfection | 1 | 2010 | 911 | 0.020 |
Why?
|
| Glioblastoma | 1 | 1990 | 265 | 0.020 |
Why?
|
| Liver | 1 | 1993 | 1208 | 0.020 |
Why?
|
| Jurkat Cells | 1 | 2007 | 77 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 727 | 0.020 |
Why?
|
| Hemoglobins | 2 | 2002 | 192 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1990 | 548 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 1984 | 31 | 0.020 |
Why?
|
| Materials Testing | 1 | 2004 | 93 | 0.010 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1984 | 47 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 969 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1994 | 2566 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2004 | 208 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2003 | 27 | 0.010 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2003 | 27 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2003 | 146 | 0.010 |
Why?
|
| Follow-Up Studies | 3 | 2001 | 3666 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2004 | 198 | 0.010 |
Why?
|
| Research Support as Topic | 1 | 2003 | 85 | 0.010 |
Why?
|
| Phosgene | 1 | 2002 | 1 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 135 | 0.010 |
Why?
|
| Cisterna Magna | 1 | 2002 | 11 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2002 | 108 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2003 | 125 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2002 | 75 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 2002 | 60 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2003 | 501 | 0.010 |
Why?
|
| Injections | 1 | 2002 | 116 | 0.010 |
Why?
|
| Phenols | 1 | 2002 | 41 | 0.010 |
Why?
|
| Asteraceae | 1 | 2002 | 4 | 0.010 |
Why?
|
| Myocardial Reperfusion | 1 | 2002 | 28 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 2003 | 154 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 2002 | 34 | 0.010 |
Why?
|
| Catalysis | 1 | 2002 | 205 | 0.010 |
Why?
|
| Mitochondria, Heart | 1 | 2002 | 50 | 0.010 |
Why?
|
| Cerebral Angiography | 1 | 2002 | 197 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2002 | 230 | 0.010 |
Why?
|
| Oxidants | 1 | 2002 | 86 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2002 | 69 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 2001 | 66 | 0.010 |
Why?
|
| Regression Analysis | 2 | 1995 | 590 | 0.010 |
Why?
|
| Perfusion | 1 | 2002 | 236 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1984 | 395 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2002 | 162 | 0.010 |
Why?
|
| Plant Extracts | 1 | 2002 | 245 | 0.010 |
Why?
|
| Sarcosine | 1 | 1999 | 2 | 0.010 |
Why?
|
| Thiocarbamates | 1 | 1999 | 6 | 0.010 |
Why?
|
| Drug Stability | 1 | 1999 | 49 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 1237 | 0.010 |
Why?
|
| Risk Factors | 2 | 2001 | 5499 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2001 | 755 | 0.010 |
Why?
|
| Mitochondria | 1 | 2001 | 553 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1997 | 188 | 0.010 |
Why?
|
| Chicago | 1 | 2001 | 1427 | 0.010 |
Why?
|
| United States | 2 | 2003 | 6989 | 0.010 |
Why?
|
| Vincristine | 1 | 1994 | 112 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 1994 | 68 | 0.010 |
Why?
|
| Genital Neoplasms, Female | 1 | 1995 | 108 | 0.010 |
Why?
|
| Methotrexate | 1 | 1994 | 250 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1994 | 302 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1994 | 301 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 1993 | 125 | 0.010 |
Why?
|
| Alcohols | 1 | 1993 | 15 | 0.010 |
Why?
|
| Horses | 1 | 1993 | 35 | 0.010 |
Why?
|
| Fluorouracil | 1 | 1994 | 561 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 155 | 0.010 |
Why?
|
| Brain | 1 | 2002 | 2285 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 1993 | 352 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1012 | 0.010 |
Why?
|
| Xanthines | 1 | 1991 | 3 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1993 | 996 | 0.010 |
Why?
|
| Acute Disease | 1 | 1993 | 841 | 0.010 |
Why?
|
| Radiation | 1 | 1990 | 15 | 0.010 |
Why?
|
| Neutrons | 1 | 1990 | 57 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1994 | 1942 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1994 | 1109 | 0.010 |
Why?
|
| Esthetics | 1 | 1989 | 45 | 0.010 |
Why?
|
| Neutrophils | 1 | 1991 | 308 | 0.010 |
Why?
|
| Hysterectomy | 1 | 1990 | 151 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1995 | 9057 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1989 | 101 | 0.010 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1989 | 116 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 312 | 0.000 |
Why?
|
| Mathematics | 1 | 1988 | 191 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1989 | 220 | 0.000 |
Why?
|
| Preoperative Care | 1 | 1990 | 396 | 0.000 |
Why?
|
| Recurrence | 1 | 1990 | 1144 | 0.000 |
Why?
|
| Survival Analysis | 1 | 1990 | 1534 | 0.000 |
Why?
|
| Clinical Trials as Topic | 1 | 1990 | 1150 | 0.000 |
Why?
|
| Keratins | 1 | 1984 | 63 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1993 | 4289 | 0.000 |
Why?
|
| Carcinoma, Small Cell | 1 | 1984 | 133 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1984 | 284 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1989 | 1365 | 0.000 |
Why?
|